Lenvatinib mesylate

Lenvatinib mesylate
Product Description

Lenvatinib mesylate (CAS No.: 857890-39-2)Indications: For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid carcinoma (DTC).

Read more Show less

KINHOO PHARMACEUTICAL CO.,LTD

  • Country/Region:
    China
  • On CPHI since:
    2017
  • Employees:
    500 - 999
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    857890-39-2
  • Supplied from
    China
More specifications Fewer specifications

KINHOO PHARMACEUTICAL CO.,LTD

  • Country/Region:
    China
  • On CPHI since:
    2017
  • Employees:
    500 - 999
Company types
Pharmaceutical company
View company profile

More Products from KINHOO PHARMACEUTICAL CO.,LTD (2)

  • Sorafenib tosylate

    Product Sorafenib tosylate

    Sorafenib tosylate (CAS No.: 475207-59-1) Indications: For the treatment of patients with advanced renal cell carcinoma (RCC). For the treatment of patients with unresectable hepatocellular carcinoma (HCC). For the treatment of patients with locally recurrent or metastatic, progressive, differentia...
  • Vardenafil hydrochloride

    Product Vardenafil hydrochloride

    Vardenafil hydrochloride (CAS No.: 330808-88-3)Indications: For the treatment of erectile dysfunction.